

Tazarotene Reformulated for the Treatment of Acne

Video References

1. Skin conditions by the numbers. American Academy of Dermatology site. <https://www.aad.org/media/stats-numbers>. Accessed 22 Sep 2021.
2. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. *J Am Acad Dermatol*. 2016;74(5):945–973.
3. Shalita AR, Berson DS, Thiboutot DM, et al. Tazarotene Cream in Acne Clinical Study Investigator Group. Effects of tazarotene 0.1% cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. *Clin Ther*. 2004; 26: 1865– 1873.
4. Webster GF, Berson D, Stein Gold L, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. *Cutis*. 2001;67:4–9.
5. Leyden J, Tanghetti E, Ling M, et al. Tazarotene 0.1 % gel versus tretinoin 0.1 % microsphere in facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Poster presentation. Maui, HI: MauiDerm 2009.
6. Epstein EL, Stein Gold L. Safety and efficacy of tazarotene foam for the treatment of acne vulgaris. *Clin Cosmet Invest Dermatol* 2013;6:123–125
7. Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. *J Drugs Dermatol*. 2005;4:153– 158.
8. Zaenglein A, Thiboutot D. Expert Committee Recommendations for Acne Management. *Pediatrics*. 2006; 118(3): 1188–1199. September 2006
9. Allergan. Tazorac® (tazarotene) Gel 0.05%, (tazarotene) Gel 0.1% product indications. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020600s008lbl.pdf. Accessed 10 Sep 2021.
10. Phillips TJ. Tazarotene 0.1% cream for the treatment of photodamage. *Skin Ther Lett*. 2004;9(4):1–2. <https://www.skintherapyletter.com/dermatology/tazarotene-cream/>
11. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. *Cutis*. 2006;77(1):45–50.
12. Tanghetti E, Draelos Z, Grimes P, et al. Moisturizer use enhances facial tolerability of tazarotene 0.1% cream without compromising efficacy in patients with acne vulgaris.

- <https://dermatologyandlasersurgery.com/wp-content/uploads/2020/01/2008-Poster-Moisturizer-Use-Enhances-Facial-Tolerability.pdf>. Accessed 10 Sep 2021.
13. Bausch Health US, LLC. ARAZLO® (tazarotene) 0.045% lotion Prescribing Information. <https://www.bauschhealth.com/portals/25/pdf/pi/arazlo-pi.pdf>. Accessed 10 Sep 2021.
 14. Tanghetti E, Kircik L, Green L, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. *J Drugs Dermatol*. 2019;18(6):542.
 15. Tanghetti EA, Werschler WP, Lain T, et al. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. *J Drugs Dermatol*. 2020;19(1):70–77.
 16. Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. *J Dermatolog Treat*. 2021;32(4):391–398.
 17. Bausch Health US, LLC. ARAZLO® (tazarotene) 0.045% lotion TEWL and corneometer study data and patient acceptance survey data on file. <https://www.arazlo.com/hcp/vehicle>. Accessed 10 Sep 2021.